CBIO (Crescent Biopharma) Equity-to-Asset : -0.44 (As of Dec. 2024)

View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Crescent Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-15.48 Mil. Crescent Biopharma's Total Assets for the quarter that ended in Dec. 2024 was $35.62 Mil.

The historical rank and industry rank for Crescent Biopharma's Equity-to-Asset or its related term are showing as below:

CBIO's Equity-to-Asset is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Equity-to-Asset only.

Crescent Biopharma Equity-to-Asset Historical Data

The historical data trend for Crescent Biopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescent Biopharma Equity-to-Asset Chart

Crescent Biopharma Annual Data

Trend

Dec24

Equity-to-Asset

-0.44

Crescent Biopharma Semi-Annual Data
	Dec24
Equity-to-Asset	-0.44

Competitive Comparison of Crescent Biopharma's Equity-to-Asset

For the Biotechnology subindustry, Crescent Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

Crescent Biopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Crescent Biopharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	-15.479	/	35.617
	=

Crescent Biopharma's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	-15.479	/	35.617
	=

Crescent Biopharma (NAS:CBIO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Crescent Biopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescent Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453

Website

https://www.crescentbiopharma.com

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.